Health Canada Imposes License Restrictions on Grifols Following Plasma Donor Deaths
Spanish pharmaceutical giant Grifols SA is facing significant regulatory action in Canada after two individuals died following plasma donations at the company's collection centers. Health Canada, the federal health policy regulator, has placed terms and conditions on Grifols' blood establishment license and issued non-compliance ratings to multiple facilities across the country.
Systemic Deficiencies Prompt Regulatory Action
Health Canada cited "recurring, systemic deficiencies across several sites" as the primary reason for imposing restrictions on Grifols' operations. The regulatory agency issued non-compliance ratings to Grifols' Canadian head office in Oakville, Ontario, along with collection sites in Calgary, Alberta and Regina, Saskatchewan. These actions come despite Health Canada's preliminary investigation finding no direct link between the plasma collection process and the fatalities.
Mark Johnson, a spokesperson for Health Canada, stated that following the deaths at Winnipeg locations, the government "identified areas of non-compliance and requested corrective actions from Grifols." The two deaths occurred in October and January at Grifols plasma collection centers in Winnipeg, with another patient filing a lawsuit alleging kidney damage caused by equipment failure.
Specific Requirements and Compliance Measures
The terms and conditions imposed by Health Canada require Grifols to implement several critical changes to their operations:
- Reducing appointment numbers to ensure staff can fully follow procedures
- Strengthening quality checks to identify and address issues quickly
- Maintaining these restrictions until Grifols demonstrates full compliance
These requirements apply to all 16 plasma collection sites operated by Grifols across Canada. Johnson emphasized that the restrictions will remain in place until the company shows satisfactory compliance with regulatory standards.
Inspection Findings at Canadian Facilities
Detailed inspections revealed specific deficiencies at multiple Grifols locations:
- Calgary and Regina Collection Sites: Inspectors found failures in accurately assessing donor suitability and inadequate validation, calibration, cleaning, and maintenance of critical equipment.
- Oakville Head Office: A virtual inspection determined insufficient staffing with appropriate education, training, and experience.
Despite these findings, Johnson noted that "there is no evidence that plasma safety or quality was affected" by the identified deficiencies. Health Canada's inspections are continuing as the regulator monitors Grifols' compliance efforts.
Company Response and Ongoing Operations
In an emailed statement, Grifols acknowledged the regulatory actions and committed to addressing deficiencies "swiftly." The company stated it is implementing Health Canada's additional terms and conditions and continues "to work collaboratively with Health Canada to ensure ongoing compliance."
Grifols emphasized that all of its Canadian donor centers remain open, with donor safety remaining the company's top priority. The pharmaceutical company declared its commitment to "maintaining a strong and consistent quality program across its Canadian donor centre network."
Broader Context and Industry Implications
The regulatory action against Grifols comes at a sensitive time for Canada's plasma collection industry. Canada remains one of the few countries that permits payment to plasma donors, creating unique regulatory challenges and industry dynamics.
Mary Hughes, Grifols' vice-president of sales in Canada, recently testified before lawmakers regarding Canada's pharmaceutical sovereignty. The company was summoned to appear following public disclosure of the plasma collection deaths, highlighting increased scrutiny on plasma collection practices and donor safety protocols.
As Health Canada continues its inspections and monitoring, the pharmaceutical industry watches closely how regulatory standards evolve for plasma collection operations. The case underscores the critical balance between maintaining adequate plasma supplies for medical treatments and ensuring rigorous donor safety protocols across all collection facilities.
